{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:58:28Z","timestamp":1781222308219,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent evidence suggests that the serum uric acid to apolipoprotein A1 ratio (UAR) may be a novel biomarker for metabolic dysfunction-associated steatotic liver disease (MASLD). This study aims to investigate the relationship between UAR and MASLD, and compare the diagnostic ability of UAR with other insulin resistance-related markers for MASLD in individuals with type 2 diabetes mellitus (T2DM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A cohort of 1,019 individuals with T2DM was recruited from the National Metabolic Management Center of our hospital. Unenhanced abdominal CT scans were performed to evaluate liver steatosis for diagnosing MASLD. The association between UAR and the risk of MASLD was analyzed using weighted binomial logistic regression, restricted cubic splines (RCS), and subgroup analysis. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic performance of UAR with other insulin resistance-related markers, including the serum uric acid to high-density lipoprotein cholesterol ratio (UHR), triglyceride to high-density lipoprotein cholesterol ratio (THR), and triglyceride to apolipoprotein A1 ratio (TAR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Participants in the MASLD group exhibited elevated UAR levels. After full adjustments for potential confounders, UAR remained independently associated with MASLD (<jats:italic>OR:<\/jats:italic> 1.65, 95% CI: 1.45-1.89, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Subgroup analyses revealed that this association was consistent across various subgroups, including sex, drinking status, hypertension, lipid-lowering therapy, and body mass index (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). RCS analysis demonstrated a linear increase in the risk of MASLD with higher UAR levels (<jats:italic>P<\/jats:italic> for nonlinear = 0.319). ROC curve analysis indicated that UAR provided good diagnostic performance for MASLD (AUC:0.777, 95% CI: 0.749- 0.805), comparable to TAR (AUC difference: -0.003, 95% CI: -0.033-0.026, <jats:italic>P<\/jats:italic> = 0.818) and superior to UHR (AUC difference: 0.043, 95% CI: 0.019-0.067, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and THR (AUC difference: 0.035, 95% CI: 0.019-0.067, <jats:italic>P<\/jats:italic> = 0.047).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>UAR was independently associated with MASLD and demonstrated significant diagnostic value, indicating that UAR could be a cost-effective biomarker to help identify high-risk individuals for MASLD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1619003","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:15:15Z","timestamp":1749010515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiu Li","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu Ping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.15403\/jgld-5901","article-title":"The mediation effects of type 2 diabetes mellitus and related biomarkers on the association of metabolic dysfunction-associated steatotic liver disease and fibrosis","volume":"34","author":"Cai","year":"2025","journal-title":"J Gastrointestinal Liver Diseases"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin gastroenterology hepatology: Off Clin Pract J Am Gastroenterological Association"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.446","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1164096","article-title":"Association of serum uric acid-to-high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease in American adults: a population-based analysis","volume":"10","author":"Xie","year":"2023","journal-title":"Front medicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/nu16091310","article-title":"Triglyceride to HDL cholesterol ratio for the identification of MASLD in obesity: A liver biopsy-based case-control study","volume":"16","author":"Mart\u00ednez-Montoro","year":"2024","journal-title":"Nutrients"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/jcm14072341","article-title":"The ability of the triglyceride-glucose (TyG) index and modified tyG indexes to predict the presence of metabolic-associated fatty liver disease and metabolic syndrome in a pediatric population with obesity","volume":"14","author":"Tamini","year":"2025","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15190.020","article-title":"Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo","volume":"5","author":"Iqbal","year":"2016","journal-title":"eLife"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12147","article-title":"APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children","volume":"12","author":"Su\u00e1rez-S\u00e1nchez","year":"2017","journal-title":"Pediatr obesity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4709300","DOI":"10.1155\/2022\/4709300","article-title":"Role of apolipoprotein A1 in PPAR signaling pathway for nonalcoholic fatty liver disease","volume":"2022","author":"Chen","year":"2022","journal-title":"PPAR Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31396","DOI":"10.1038\/s41598-024-82994-4","article-title":"Monocytes to Apolipoprotein A1 ratio is associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1384059","article-title":"Triglycerides to apolipoprotein A1 ratio: an effective insulin resistance-associated index in identifying metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.446","article-title":"Serum uric acid to high-density lipoprotein ratio as a novel indicator of inflammation is correlated with the presence and severity of metabolic syndrome: A large-scale study","volume":"6","author":"Kolahi Ahari","year":"2023","journal-title":"Endocrinology Diabetes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Internal medicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14246","article-title":"Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD","volume":"15","author":"Ito","year":"2024","journal-title":"J Diabetes investigation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.3390\/nu16223857","article-title":"Weight loss after sleeve gastrectomy according to metabolic dysfunction-associated steatotic liver disease stage in patients with obesity: A liver biopsy-based prospective study","volume":"16","author":"Mart\u00ednez-Montoro","year":"2024","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: an immunometabolic perspective","volume":"20","author":"Schw\u00e4rzler","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.v59.s1","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","author":"Bansal","year":"2024","journal-title":"Alimentary Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1415484","article-title":"Association of systemic immune biomarkers with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study of NHANES 2007-2018","volume":"11","author":"Wang","year":"2024","journal-title":"Front nutrition"},{"key":"B23","doi-asserted-by":"publisher","first-page":"30403","DOI":"10.1038\/s41598-024-80801-8","article-title":"Predictive role of neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index for mortality in patients with MASLD","volume":"14","author":"Dong","year":"2024","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12876-024-03394-6","article-title":"Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1491858","article-title":"Association between neutrophil-to-high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2017-2020","volume":"11","author":"Zhu","year":"2024","journal-title":"Front medicine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.898931","article-title":"Association between monocyte to\u00a0high-density lipoprotein cholesterol ratio and risk of non-alcoholic fatty liver disease:\u00a0A cross-sectional study","volume":"9","author":"Wang","year":"2022","journal-title":"Front medicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-024-2919-6","article-title":"Monocyte to high-density lipoprotein cholesterol ratio as a predictor of nonalcoholic fatty liver disease in childhood obesity","volume":"44","author":"Zhang","year":"2024","journal-title":"Curr Med science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6642246","DOI":"10.1155\/2021\/6642246","article-title":"Association between monocyte to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: A cross-sectional study","volume":"2021","author":"Huang","year":"2021","journal-title":"Mediators inflammation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.981196","article-title":"Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","article-title":"Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease","volume":"23","author":"Colantoni","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","article-title":"Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.3390\/nu14234969","article-title":"The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): A systematic review and meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13098-024-01571-x","article-title":"Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus","volume":"17","author":"Hu","year":"2025","journal-title":"Diabetol Metab syndrome"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14086","article-title":"Association between serum uric acid-to-high-density lipoprotein cholesterol ratio and insulin resistance in patients with type 2 diabetes mellitus","volume":"15","author":"Zhou","year":"2024","journal-title":"J Diabetes investigation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12944-024-02404-6","article-title":"Gender differences in the association between the uric acid to high-density lipoprotein cholesterol ratio and diabetes risk: a mediation analysis of c-reactive protein, triglycerides, and insulin resistance","volume":"23","author":"Yin","year":"2024","journal-title":"Lipids Health disease"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1474384","article-title":"Association between serum uric acid-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease among Chinese children with obesity","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-024-03190-2","article-title":"Using new indices to predict metabolism dysfunction-associated fatty liver disease (MAFLD): analysis of the national health and nutrition examination survey database","volume":"24","author":"Li","year":"2024","journal-title":"BMC Gastroenterol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1619003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:15:15Z","timestamp":1749010515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1619003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":37,"alternative-id":["10.3389\/fendo.2025.1619003"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1619003","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1619003"}}